Group 1 - The core point of the article is that Guobang Pharmaceutical held its first temporary board meeting for 2025 on November 6, 2023, to discuss the appointment of the board secretary and other documents [1] - For the year 2024, Guobang Pharmaceutical's revenue composition is as follows: the pharmaceutical segment accounts for 64.87%, the animal health products segment accounts for 34.24%, and other segments account for 0.48% and 0.4% respectively [1] - As of the report date, Guobang Pharmaceutical has a market capitalization of 12.5 billion yuan [1]

本员工持股计划初始拟筹集资金总额不超过18,500万元，其中员工自筹资金不超过18,500万元，具体金 额根据实际出资缴款金额确定。本员工持股计划的资金来源为员工合法薪酬、自筹资金以及法律法规允 许的其他方式。上市公司不得向员工提供财务资助或为其贷款提供担保。 格隆汇11月6日丨国邦医药(605507.SH)公布第二期员工持股计划，本员工持股计划的参加对象为对公司 整体业绩和中长期发展具有重要作用和影响的公司（含合并报表子公司，下同）董事（不含独立董 事）、高级管理人员、中层管理人员及核心技术（业务）骨干，总人数不超过270人，其中参加持股计 划的董事（不含独立董事）和高级管理人员共计8人。 ...

Core Viewpoint - Guobang Pharmaceutical (605507.SH) has disclosed the draft for its second employee stock ownership plan, aimed at enhancing the company's overall performance and long-term development [1] Group 1: Employee Stock Ownership Plan - The participants of the employee stock ownership plan include directors (excluding independent directors), senior management, middle management, and key technical (business) personnel, totaling no more than 270 individuals [1] - Among the participants, there are 8 directors (excluding independent directors) and senior management members involved in the plan [1] - The initial total amount of funds to be raised through the employee stock ownership plan is set to not exceed 185 million yuan, with employee self-raised funds also capped at 185 million yuan [1]

格隆汇11月6日丨国邦医药(605507.SH)公布第二期员工持股计划，本员工持股计划的参加对象为对公司 整体业绩和中长期发展具有重要作用和影响的公司（含合并报表子公司，下同）董事（不含独立董 事）、高级管理人员、中层管理人员及核心技术（业务）骨干，总人数不超过270人，其中参加持股计 划的董事（不含独立董事）和高级管理人员共计8人。 本员工持股计划初始拟筹集资金总额不超过18,500万元，其中员工自筹资金不超过18,500万元，具体金 额根据实际出资缴款金额确定。本员工持股计划的资金来源为员工合法薪酬、自筹资金以及法律法规允 许的其他方式。上市公司不得向员工提供财务资助或为其贷款提供担保。 ...

智通财经APP讯，国邦医药(605507.SH)披露第二期员工持股计划(草案)，参加对象为对公司整体业绩和 中长期发展具有重要作用和影响的公司(含合并报表子公司)董事(不含独立董事)、高级管理人员、中层 管理人员及核心技术(业务)骨干，总人数不超过270人，其中参加持股计划的董事(不含独立董事)和高级 管理人员共计8人。员工持股计划初始拟筹集资金总额不超过1.85亿元，其中员工自筹资金不超过1.85亿 元。 ...

Group 1 - The company Guobang Pharmaceutical (605507.SH) announced a share buyback program, having repurchased a total of 5.3753 million shares as of October 31, 2025, which represents 0.96% of the company's total share capital [1] - The highest transaction price during the buyback was 19.88 yuan per share, while the lowest was 18.61 yuan per share [1] - The total amount spent on the buyback, excluding transaction fees, was 103 million yuan [1]

Summary of Key Points Core Viewpoint - Guobang Pharmaceutical (605507.SH) has announced a share buyback program, indicating a commitment to enhancing shareholder value through capital management strategies [1] Group 1: Share Buyback Details - As of October 31, 2025, the company has repurchased a total of 5.3753 million shares [1] - The repurchased shares account for 0.96% of the company's total share capital [1] - The highest transaction price during the buyback was 19.88 CNY per share, while the lowest was 18.61 CNY per share [1] - The total amount paid for the buyback, excluding transaction fees, is 103 million CNY [1]

重要内容提示： | 回购方案首次披露日 | 2025/3/11 | | --- | --- | | 回购方案实施期限 | 2025/3/11~2026/3/10 | | 预计回购金额 | 1亿元~2亿元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 5,375,274股 | | 累计已回购股数占总股本比例 | 0.96% | | 累计已回购金额 | 102,600,172.21元 | | 实际回购价格区间 | 18.61元/股~19.88元/股 | 证券代码：605507 证券简称：国邦医药 公告编号：2025-049 国邦医药集团股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 截至 2025 年 10 月 31 日，公司通过集中竞价交易方式累计回购股份 5,375,274 股，已回购股份占公司总股本的比例为 0.96%，成交的最高价为 19.88 元/股，最低 价为 ...

国邦医药（605507）(605507.SH)发布公告，截至2025年10月31日，公司通过集中竞价交易方式累计回 购股份537.53万股，已回购股份占公司总股本的比例为0.96%，成交的最高价为19.88元/股，最低价为 18.61元/股，已支付的总金额为1.03亿元(不含交易费用)。 ...

Core Viewpoint - The company announced a share repurchase plan aimed at enhancing employee stock ownership and equity incentives, with a total repurchase amount expected to be between 100 million to 200 million yuan [1] Group 1 - The share repurchase will be conducted through centralized bidding and is set to last until March 10, 2026 [1] - As of October 31, 2025, the company has repurchased a total of 5.3753 million shares, which represents 0.96% of the total share capital [1] - The highest transaction price recorded during the repurchase was 19.88 yuan per share, while the lowest was 18.61 yuan per share, with a total expenditure of 103 million yuan [1]